Concepedia

Author

Dirk Nagorsen

Amgen (United States)ORCID

Also Known As

D Nagorsen, D. Nagorsen, Dirk Nagorsen, Nagorsen, D, Nagorsen, D., Nagorsen, Dirk

131

Publications

11.2K

Citations

40

H-Index

61

Concepts

All Affiliations

Amgen (United States)Amgen (Germany)Charité - Universitätsmedizin BerlinUniversity Hospital Schleswig-HolsteinUniversity of Lübeck
DN

About

Dirk Nagorsen is an author at Amgen (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

22

2.3K

2

Immunology

14

19

1K

3

Cell Biology

8

8

422

4

Health Sciences

3

3

48

5

Natural Sciences

1

1

13

Dirk Nagorsen

×

63

Publications

9.9K

Citations

33

H-Index

YearCitations

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget,

New England Journal of Medicine

2017

2K

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein,

The Lancet Oncology

2014

1.2K

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget,

Journal of Clinical Oncology

2011

902

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio,

Blood

2018

810

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier,

Blood

2012

466

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier,

Blood

2012

459

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot,

Journal of Clinical Oncology

2016

414

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Andreas Viardot, Marie-Elisabeth Goebeler, Svenja Neumann,

Blood

2016

358

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Carmen Scheibenbogen, Anne Letsch, Eckhard Thiel,

Blood

2002

250

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai,

Journal of Clinical Oncology

2023

250

Page 1